A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)-Reference-Cited by-同舟云学术

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)

Published:2021-07 Issue:4 Volume:22 Page:313-323.e1
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Argiris Athanassios,Miao Jieling,Cristea Mihaela C.,Chen Allen M.,Sands Jacob M.,Decker Roy H.,Gettinger Scott N.,Daly Megan E.,Faller Bryan A.,Albain Kathy S.,Yanagihara Ronald H.,Garland Linda L.,Byers Lauren A.,Wang Ding,Koczywas Marianna,Redman Mary W.,Kelly Karen,Gandara David R.

Funder

NCI

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. Lung cancer statistics;Torre;Adv Exp Med Biol,2016

2. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Auperin;J Clin Oncol,2010

3. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data;Santana-Davila;J Clin Oncol,2015

4. Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non-small-cell lung cancer: a systematic review;Steuer;JAMA Oncol,2017

5. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer;Salama;J Clin Oncol,2013

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the benefits and safety profile of incorporating poly ADP-ribose polymerase (PARP) inhibitors in the treatment of advanced lung cancer: a thorough systematic review and meta-analysis;Frontiers in Pharmacology;2024-06-21

2. Veliparib‑Induced Toxicity in Cancer Patients: A Systematic Review and Meta‑Analysis;Cancer Investigation;2024-03-15

3. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review;Translational Lung Cancer Research;2024-02

4. Arterial hypertension associated with PARPi: A meta‐analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study;Fundamental & Clinical Pharmacology;2024-01-25

5. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis;Chinese Clinical Oncology;2023-12